2c2c7f46-2271-42fb-9857-05de4bc0aee6
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- MITOTIC_SPINDLE+0.500
- G2M_CHECKPOINT+0.400
- MYC_TARGETS_V1+0.400
- MYC_TARGETS_V2+0.400
- INTERFERON_ALPHA_RESPONSE+0.300
- FATTY_ACID_METABOLISM+0.200
- MTORC1_SIGNALING+0.200
- NOTCH_SIGNALING+0.200
- UV_RESPONSE_DN+0.200
Top 10 suppressed
- ESTROGEN_RESPONSE_LATE-0.300
- HYPOXIA-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- PANCREAS_BETA_CELLS-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- CHOLESTEROL_HOMEOSTASIS-0.200
- ESTROGEN_RESPONSE_EARLY-0.200
- KRAS_SIGNALING_DN-0.200
- APICAL_SURFACE-0.100
- COAGULATION-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934957 | — | — | 0.813 |
| 2 | d708a0d7-edda-46a8-b717-1b48c073c828 | — | — | 0.812 |
| 3 | SRR934919 | — | — | 0.791 |
| 4 | MDT-AP-3168 | Med | Medulloblastoma | 0.784 |
| 5 | SRR934751 | — | — | 0.784 |
| 6 | CBB97C4E-43C7-4257-A85E-1F72BA71EF91 | — | — | 0.775 |
| 7 | A84E45CA-971F-45D8-B7C7-E3562F2B51F3 | — | — | 0.769 |
| 8 | SRR934757 | — | — | 0.769 |
| 9 | SRR934887 | — | — | 0.768 |
| 10 | sclcF3905_S59.txt | — | cohortMD1 | 0.764 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |